Towards the regulation of research ethics boards;Pour une réglementation des Comités d'éthique de la recherche

Canadian Journal of Anesthesia

Volumn 49, Issue 9, 2002, Pages 900-906

  Bevan, Joan C ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANADA; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL STUDY; CONTROLLED STUDY; FINANCIAL MANAGEMENT; GENE THERAPY; GOOD CLINICAL PRACTICE; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; INFORMED CONSENT; LAW SUIT; MEDICAL DECISION MAKING; MEDICAL ETHICS; MEDICAL RECORD; MEDICAL RESEARCH; MEDICOLEGAL ASPECT; PATIENT CARE; PATIENT RIGHT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPONSIBILITY; RISK ASSESSMENT; STANDARDIZATION;

EID: 0036873379     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03016871     Document Type: Article

References (14)

1. Thompson J, Baird P, Downie J. Committee of inquiry on the case involving Dr. Nancy Olivieri, the Hospital for Sick Children, the University of Toronto, and Apotex Inc. Section D Recommendations 10-14 www.dal.ca/committeeofinquiry/
2. Kolata G. Media report: U.S. suspends human research at John Hopkins after death. The New York Times July 20, 2001 and Research volunteer death. John Hopkins Medicine, Press releases. http://www.hopkinsmedicine.org/press/index.html
3. Sibbald B. Death but one unintended consequence of gene-therapy trial. CMAJ 2001; 164: 1612.
4. Rioux P. Media report: Baltimore lead abatement study faulted by court. IRED.com, Inc. September 10, 2001 and Kennedy Kreiger Institute, Johns Hopkins response to Court of Appeals ruling in lead paint case. Johns Hopkins Medicine, Press Releases http://www.hopkinsmedicine.org/press/index.html
5. Knoppers BM, Lowy FH, Naimark A. Clinical trials of L1 (Deferiprone) at The Hospital for Sick Children: a review of facts and circumstances. http://www.sick-kids.ca/L1trials/revcontents.asp
6. Levine RJ. Institutional Review Boards: a crisis in confidence (Editorial). Ann Int Med 2001; 134: 161-3.
7. Hampton JR. Clinical trial safety committees: the devil's spoon. BMJ 2000; 320: 244-5.
8. Anonymous. Federal policy for the protection of human subjects ("Common Rule"). Federal Register 1991; 56: 28002 and the Common Rule 1991. Introduction to human subject and privacy protections at the National Institute of Justice. wysiwyg://45/http://www.ojp.usdoj.gov/nij/humansubjects/hs_01.html
9. Burman WJ, Reves RR, Cohn DL, Schooley RT. Breaking the camel's back: multicenter clinical trails and local institutional review boards. Ann Intern Med 2001; 134: 152-7.
10. Tri-Council policy statement: ethical coduct for research involving humans. August 1998. http://www.nserc.ca/programs/ethics/english/policy.htm
11. Weijer C. Placebo trials and tribulations. CMAJ 2002; 166: 603-4.
12. Hirtle M, Lemmens T, Sprumont D. A comparative analysis of research ethics review mechanisms and the ICH good clinical practice guideline. European Journal of Health Law 2000; 7: 265-92.
13. Naylor CD. Early Toronto experience with new standards for industry-sponsored clinical research: a progress report. CMAJ 2002; 166: 453-6.
14. Anonymous. Look, no strings: publishing industry-funded research (Editorial). CMAJ 2001; 165: 733.